Table 1_Discovery of plasma metabolomic biomarkers and a predictive model for immune checkpoint inhibitor-associated myocarditis: a pilot case-control study.docx

This exploratory pilot case-control study aimed to characterize baseline plasma metabolomic profiles in patients who developed ICI-associated myocarditis and to evaluate a metabolite-based predictive model.</p>Methods<p>Baseline plasma samples from 15 patients with ICI-associated myocarditis and 15 matched controls were analyzed by untargeted metabolomics using UHPLC-Q/Orbitrap HRMS.

Differential metabolites were identified by OPLS-DA and univariate analysis. A metabolite-derived PC1 was used in logistic regression models (clinical-only, metabolite-only, combined), with performance assessed by AUC.</p>Results<p>Ten differential metabolites were identified, implicating glutathione metabolism, phenylalanine metabolism, and histidine metabolism pathways. Key alterations included elevated phenylpyruvic acid, 1-methylpseudouridine, cinnamoylglycine, pyroglutamic acid and spermine, with decreased ceramide, cyclo-prolylglycine, propionic acid, glycolic acid, and histamine.